Study Results Demonstrate A New Prostate Cancer Treatment

Share this content:

the ONA take:

A new study is suggesting a different approach to treating prostate cancer. Researchers at Comprehensive Cancer Centers of Nevada conducted a study in which 790 men with advanced stages of prostate cancer received early chemotherapy. Typically, patients undergo hormone therapy before introduction to chemotherapy drugs such as docetaxel. All of the participants in this study had advanced prostate cancer; either the cancer had metastasized at diagnosis, or they had recurrent disease after radiation or surgery. The study results showed that those patients who received docetaxel survived an average of almost 14 months longer than those who did not receive chemotherapy. Although this study demonstrates the benefits of starting chemotherapy early in the course of treatment, one coauthor pointed out that patients are often reluctant to undergo chemotherapy.

Study Results Demonstrate A Prostate Cancer Treatment
Study Results Demonstrate A Prostate Cancer Treatment
A new study suggests that early chemotherapy can provide significant benefits, and may be the key to increased survival rates. The findings are being talked about across the oncology community, and may even change the way we approach prostate cancer treatment in the future. Vogelzang, an oncologist at Comprehensive Cancer Centers of [ ].
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs